Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Glioma 11Glioblastoma 6Brain Neoplasms 4Neuroendocrine Tumors 3Hypoglycemia 3Congenital Hyperinsulinism 3Recurrence 2Parkinson Disease 2Oligodendroglioma 2Neuroblastoma 2Insulinoma 2Hyperinsulinism 2Gliosarcoma 2Ependymoma 2Astrocytoma 2Pheochromocytoma 1Parkinsonian Disorders 1Parathyroid Neoplasms 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Endocrine Neoplasia 1Lewy Body Disease 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hypercalcemia 1Glucose Metabolism Disorders 1Glioma, Subependymal 1Endocrine System Diseases 1Carcinoma, Medullary 1

Interventions

fluorodopa F 18 1Referral and Consultation 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lewy Body Disease × fluorodopa F 18 × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡